cd38 inhibitor and 5-amino-1mq synergy nad+

cd38 inhibitor and 5-amino-1mq synergy nad+ as theranostic target in oncology | Journal of Translational Medicine Rapid Discovery of CD38 Inhibitor

Name: cd38 inhibitor and 5-amino-1mq synergy nad+ as theranostic target in oncology | Journal of Translational Medicine Rapid Discovery of CD38 Inhibitor
Brand: meijijudolehavre.com
SKU: 76069221773
Price: 21.57 USD
Availability: InStock
Rating: 4.081 (10 reviews)

Rapid Discovery of CD38 Inhibitor via DNA Encoded Natural Product Library Screening CD38 as a Regulator of Cellular NAD: A Novel Potential Pharmacological Target for Metabolic Conditions PMC CD38 Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+ Lowering Agents SLC25A51 decouples the mitochondrial NAD+ NADH ratio to control proliferation of AML cells: Cell Metabolism Evolving roles of CD38 metabolism in solid tumour microenvironment British Journal of Cancer Targeting NAD+ Synthesis to Potentiate CD38 Based Immunotherapy of Multiple Myeloma ScienceDirect

SKU: 76069221773 · From meijijudolehavre.com

4.1

USD21.57 USD42.57

Pay in 4 interest-free payments of $5.39 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 2 - Aug 7

Description

A novel target for next-generation obesity medications is nicotinamide N-methyltransferase (NNMT) 7,8,9,10,11 , an enzyme central to cellular metabolism and energy homeostasis 12